Document Detail

If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
MedLine Citation:
PMID:  16752230     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: This case-control study was performed to evaluate whether adding first-trimester maternal serum testing to nuchal translucency measurement would improve the antenatal detection of Down's syndrome and decrease the number of women offered fetal karyotyping. METHODS: In the Swedish Nuchal Translucency Trial (the NUPP trial), 39,572 pregnant women were randomized to a routine scan at 12-14 gestational weeks including nuchal translucency screening for Down's syndrome, or a routine scan at 16-18 gestational weeks. From the early scan group 47 pregnancies with Down's syndrome were identified and for each case three controls were chosen. Of the 189 women asked to participate, 31 cases and 108 controls with a singleton pregnancy and frozen serum from 8-14 gestational weeks available for analysis accepted participation. Maternal sera were analyzed for free beta human chorionic gonadotrophin and pregnancy-associated plasma protein A. The risk for Down's syndrome was calculated using combinations of maternal age, crown-rump length, nuchal translucency, and biochemistry. A risk > or =1/250 was considered increased and an indication for fetal karyotyping. RESULTS: Risk calculated on the basis of maternal age alone would have identified 21 of the 31 Down's syndrome cases by karyotyping 61 of the 139 fetuses. Maternal age and nuchal translucency would have identified 29 cases by karyotyping 51 fetuses. Maternal age, nuchal translucency, and biochemistry would also have identified 29 cases by karyotyping 37 fetuses. CONCLUSIONS: By adding first trimester biochemistry to nuchal translucency measurement the detection rate of fetuses with Down's syndrome seems to remain unchanged whereas the antenatal risk group to be offered fetal karyotyping decreases.
Anna Marsk; Charlotta Grunewald; Sissel Saltvedt; Lil Valentin; Harald Almström
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Acta obstetricia et gynecologica Scandinavica     Volume:  85     ISSN:  0001-6349     ISO Abbreviation:  Acta Obstet Gynecol Scand     Publication Date:  2006  
Date Detail:
Created Date:  2006-06-05     Completed Date:  2006-06-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370343     Medline TA:  Acta Obstet Gynecol Scand     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  534-8     Citation Subset:  IM    
Ultragyn, Odengatan 69, 8tr, S-113 22 Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Case-Control Studies
Chorionic Gonadotropin, beta Subunit, Human / blood*
Chorionic Villi Sampling
Down Syndrome / blood,  diagnosis*
Maternal Age
Nuchal Translucency Measurement*
Predictive Value of Tests
Pregnancy Trimester, First
Pregnancy-Associated Plasma Protein-A / analysis*
Risk Assessment
Reg. No./Substance:
0/Chorionic Gonadotropin, beta Subunit, Human; EC 3.4.24.-/Pregnancy-Associated Plasma Protein-A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pregnancy complications by overweight and residential area. A prospective study of an urban Norwegia...
Next Document:  Risk factors in developing pregnancy-related pelvic girdle pain.